Kyowa Kirin Invests $330M in Kura’s Leukemia Drug, Gaining Shared Rights Ahead of FDA Submission

Here is the rewritten information with a Title, keywords, and key facts:

Investment Amount:
Kyowa Kirin has invested $330 million to share rights to Kura's leukemia drug.

Partnership:
The investment grants Kyowa Kirin shared rights to the drug, indicating a collaborative approach to its development and commercialization.

FDA Submission:
The investment comes ahead of Kura's planned submission to the FDA, signaling a push towards regulatory approval.

Drug Development:
The leukemia drug is a significant focus for Kura, with this partnership potentially accelerating its path to market.

Strategic Move:
Kyowa Kirin's investment is a strategic move to expand its portfolio and leverage Kura's innovative drug development.